Zura(ZURA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates HENDERSON, Nev. – (BUSINESS WIRE) – August 14, 2025 – Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. Torudokimab Zura Bio ...